CASE Op-Ed – Washington Times: Hospital Pre-payment is the Wrong Response to Beating Covid-19
Gerard Scimeca – Chairman, CASE April 16, 2020 In news that should surprise absolutely nobody, America’s healthcare professionals have...
CASE Op-Ed – InsideSources: Government Mandates Are Wrong Solution to Surprise Medical Bills
Gerard Scimeca – Chairman, CASE October 8, 2019 There is an impulse among some lawmakers that whatever the problem, more...
CASE Op-Ed, Washington Times: No ‘Magic Pill’ for Lowering Costs
Gerard Scimeca – Chairman, CASE April 5, 2019 – https://bit.ly/2IfnhvI In the ongoing public debate on the best way to effectuate...
The Problem With Price Caps: Why CMS Should Rethink Its Part B Proposal
This week, we submitted comments to Health and Human Services (HHS) Secretary Alex Azar, urging him to reevaluate and abandon...
CASE Op-Ed: Idaho Health Plan Well Intentioned But Serves As Misguided Precedent
MATTHEW KANDRACH President, CASE February 12, 2018 – http://bit.ly/2o1kiuZ While health care has largely been eclipsed in national media, significant...
.@POTUS’ IRA is driving up Part D premiums for millions of Medicare beneficiaries, yet Dems like @SenSanders continue to help tout this disastrous legislation. The Biden-Harris @WhiteHouse is misleading the public on their policy’s real impact.
Two weeks from election day, the supposedly independent @FCC is proposing price regulation of #broadband by restricting what data plans companies can offer.
By prohibiting usage-based plans, the FCC would end up increasing prices FOR EVERYONE, including low-data users!
CASE Letter Urges FDA & FTC to Scrutinize Deal Between L’Oréal and Galderma -- "Both companies are currently under investigation or facing sizable lawsuits from claims that they have used harmful chemicals in their products."
https://caseforconsumers.org/2024/10/21/case-letter-urges-fda-ftc-to-scrutinize-deal-between-loreal-and-galderma/